161.73

+2.56%↑

93.32

+1.91%↑

BMO

135.42

+2.9%↑

94.74

+3.18%↑

BNS

69.28

+2.87%↑

161.73

+2.56%↑

93.32

+1.91%↑

BMO

135.42

+2.9%↑

94.74

+3.18%↑

BNS

69.28

+2.87%↑

161.73

+2.56%↑

93.32

+1.91%↑

BMO

135.42

+2.9%↑

94.74

+3.18%↑

BNS

69.28

+2.87%↑

161.73

+2.56%↑

93.32

+1.91%↑

BMO

135.42

+2.9%↑

94.74

+3.18%↑

BNS

69.28

+2.87%↑

161.73

+2.56%↑

93.32

+1.91%↑

BMO

135.42

+2.9%↑

94.74

+3.18%↑

BNS

69.28

+2.87%↑

Начало・Списък с акции・Walker & Dunlop Inc

Walker & Dunlop Inc

Затворен

СекторФинансови

44.37 2.07

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

42.98

Максимум

44.55

Ключови измерители
By Trading Economics
Приходи	-47M -14M
Продажби	2.3M 340M
P/E Средно за сектора	27.134 54.484
Дивидентна доходност	6.12
Марж на печалбата	-4.087
Служители	1,466
EBITDA	-46M 60M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+49.46% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	6.12% 4.92%
Следващи печалби	30.04.2026 г.
Следваща дата на дивидент	28.05.2026 г.
Следваща дата на екс-дивидент	14.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-571M 1.5B
Предишно отваряне	42.3
Предишно затваряне	44.37

Настроения в новините

By Acuity

50%

171 / 441 Класиране в Finance

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

70.995 / 76.69 Подкрепа & съпротива

Walker & Dunlop Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.03.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Nike, RH, NCino

31.03.2026 г., 22:35 ч. UTC

Печалби

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1.04.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31.03.2026 г., 23:50 ч. UTC

Придобивния, сливания и поглъщания

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31.03.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31.03.2026 г., 23:21 ч. UTC

Печалби

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31.03.2026 г., 23:14 ч. UTC

Пазарно говорене

Печалби

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31.03.2026 г., 23:12 ч. UTC

Пазарно говорене

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss Widens >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31.03.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31.03.2026 г., 21:36 ч. UTC

Пазарно говорене

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects China Sales Down 20% in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31.03.2026 г., 21:33 ч. UTC

Печалби

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31.03.2026 г., 21:32 ч. UTC

Печалби

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31.03.2026 г., 21:28 ч. UTC

Печалби

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31.03.2026 г., 21:26 ч. UTC

Печалби

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31.03.2026 г., 21:25 ч. UTC

Печалби

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31.03.2026 г., 21:24 ч. UTC

Пазарно говорене

Печалби

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31.03.2026 г., 21:21 ч. UTC

Печалби

Nike's Digital Channel Still Too Promotional, CFO Says

31.03.2026 г., 21:20 ч. UTC

Печалби

Nike CEO: Converse Remains Important to Portfolio

Сравнение с други в отрасъла

Ценова промяна

Walker & Dunlop Inc Прогноза

Ценова цел

By TipRanks

49.46% нагоре

12-месечна прогноза

Среден 65 USD 49.46%

Висок 65 USD

Нисък 65 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Walker & Dunlop Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Walker & Dunlop Inc през последните 3 месеца.

Техническа оценка

By Trading Central

70.995 / 76.69Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

There are no events.

Настроение

By Acuity

171 / 441 Класиране в Финансови

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Walker & Dunlop Inc

Walker & Dunlop, Inc. is a holding company, which conducts its operations through Walker & Dunlop, LLC. The Company provides commercial real estate and financial services. It originates, sells, and services a range of commercial real estate debt and equity financing products and provides multifamily property sales brokerage and valuation services. It is also engaged in commercial real estate investment management activities. The Company provides housing market research and delivers real estate-related investment banking and advisory services. Through its agency products, the Company originates and sells loans pursuant to the programs of the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and the Federal Housing Administration. Through its debt brokerage products, the Company brokers, and in some cases services, loans for various life insurance companies, commercial banks, commercial mortgage-backed securities issuers and other institutional investors.